
Allovir Inc (KLRS) Stock Forecast & Price Target
Allovir Inc (KLRS) Analyst Ratings
Bulls say
Kalaris Therapeutics Inc. presents a promising outlook due to its development of TH103, a novel anti-VEGF drug designed for enhanced retinal retention and durability, which could lead to significant competitive advantages in the retinal disease market. The success of Vabysmo, which exceeded $4 billion in global sales and garnered a favorable positioning among retinal specialists, underscores the potential for substantial market gains from incremental improvements in anti-VEGF therapies. Additionally, key preclinical findings demonstrating TH103's complete inhibition of VEGF-induced endothelial cell proliferation, alongside its superior retinal retention compared to existing treatments like Eylea, bolster confidence in its potential effectiveness and market acceptance.
Bears say
Kalaris Therapeutics Inc., as a clinical-stage biopharmaceutical company, has not yet commercialized any products and faces the challenge of establishing the infrastructure necessary for launching its lead therapy, TH103, which may prolong its path to revenue generation. The company is expected to continue incurring significant net losses until the potential commercialization of TH103, with ongoing financial risks exacerbated by market competition from existing and new therapies targeting similar indications. Additionally, the possibility of delays in clinical development, regulatory approvals, or commercialization could lead to extended development periods and increased costs, further diminishing the financial outlook for Kalaris Therapeutics.
This aggregate rating is based on analysts' research of Allovir Inc and is not a guaranteed prediction by Public.com or investment advice.
Allovir Inc (KLRS) Analyst Forecast & Price Prediction
Start investing in Allovir Inc (KLRS)
Order type
Buy in
Order amount
Est. shares
0 shares